Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 21Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 4Triple Negative Breast Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Patient Preference 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1

Interventions

Pemetrexed 40Cisplatin 35pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Drug Therapy 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Oxaliplatin 3Imatinib Mesylate 3Fluorouracil 3Cerebral Decortication 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × decitabine and cedazuridine drug combination × Clear all
NCT05960773 2026-05-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 2 Suspended
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡